Oncternal Financial Statements From 2010 to 2025
Oncternal Therapeutics financial statements provide useful quarterly and yearly information to potential Oncternal Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Oncternal Therapeutics financial statements helps investors assess Oncternal Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Oncternal Therapeutics' valuation are summarized below:Oncternal Therapeutics does not presently have any trending fundamental ratios for analysis.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Check Oncternal Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncternal Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Oncternal financial statements analysis is a perfect complement when working with Oncternal Therapeutics Valuation or Volatility modules.
Oncternal |
Oncternal Therapeutics Company Return On Equity Analysis
Oncternal Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Oncternal Therapeutics Return On Equity | -1.5 |
Most of Oncternal Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncternal Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Oncternal Therapeutics has a Return On Equity of -1.4986. This is 93.75% lower than that of the Biotechnology sector and 95.89% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Oncternal Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Oncternal Therapeutics's current stock value. Our valuation model uses many indicators to compare Oncternal Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oncternal Therapeutics competition to find correlations between indicators driving Oncternal Therapeutics's intrinsic value. More Info.Oncternal Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Oncternal Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Oncternal Stock
If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |